COMMENTARY

Motility and visceral sensation

Functional dyspepsia: bye-bye to PPIs

O Nyrén

Department of Medical Epidemiology, Karolinska Institutet, Box 281, S-171 77 Stockholm, Sweden; olof.nyren@mep.ki.se

---

Absence of therapeutic benefit of proton pump inhibitor therapy among Chinese patients with functional dyspepsia

---

Keywords: functional dyspepsia; proton pump inhibitor; Chinese

The first 150 words of the full text of this article appear below.

When specifically asked, a significant proportion of the adult population reports dyspepsia—that is, pain or discomfort in the upper abdomen. The prevalence reported in the literature varies from 25% to 30%. Although only one in four patients with dyspepsia in the UK and USA sees a doctor for their symptoms^1–4 dyspepsia accounts for up to 5% of consultations in family practice.⁵ When appropriately investigated, less than half have an underlying structural explanation for symptoms such as peptic ulcer or reflux oesophagitis. The remainder are classified as having functional dyspepsia. The vast number of patients with functional dyspepsia, and the usually chronic or recurrent nature of this ailment, creates an enormous market for the drug industry. In spite of the obvious difficulties in delimiting the patient population, and the absence of hard end points, a fair number of—mostly industry initiated—controlled trials have been conducted. However, regardless of . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients

W M Wong, B C Y Wong, W K Hung, Y K Yee, A W C Yip, M L Szeto, F M Y Fung, T S M Tong, K C Lai, W H C Hu, M F Yuen, and S K Lam
Gut 2002 51: 502-506. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Veldhuyzen Van Zanten, S. J O (2008). Pitfalls in designing trials of functional dyspepsia: the ascent and demise of itopride. Gut 57: 723-724 [Full Text]